Wells Fargo lowered the firm’s price target on Apellis to $53 from $76 and keeps an Equal Weight rating on the shares. The firm reran its Syfovre survey from March and found its ramp already moderating plus more docs unlikely to use at all. This, compounded with the ASRS note and unclear path to remedy, leads Wells to lower estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis price target lowered to $72 from $100 at JPMorgan
- Biotech Alert: Searches spiking for these stocks today
- Stifel ‘cautious but not fatalistic’ about Syfovre, reiterates Buy on Apellis
- Unusually active option classes on open July 18th
- Apellis safety warning unlikely to have big impact, says H.C. Wainwright